Diagnosis dan Tata Laksana Dermatitis Herpetiformis
DOI:
https://doi.org/10.55175/cdk.v49i5.232Keywords:
Dapson, dermatitis herpetiformis, glutenAbstract
Dermatitis herpetiformis (DH) merupakan penyakit kulit autoimun kronik-residif akibat proses sekunder hipersensitivitas terhadap gluten. Kejadian DH tinggi pada populasi dengan predisposisi genetik HLA-DQ2 atau DQ8. Manifestasi klinis DH berupa lesi polimorfik ruam papulo-vesikular atau papul-eskoriasi didominasi rasa gatal. Baku emas diagnosis DH adalah pada pemeriksaan DIF didapatkan deposit imunoglobulin (Ig)-A granular di stratum papila dermis. Diet bebas gluten merupakan tata laksana utama. Dapson menjadi obat pilihan pertama. Prognosis baik dengan diagnosis dan tata laksana yang tepat.
Dermatitis herpetiformis (DH) is a chronic-recurrent autoimmune skin disease caused by secondary hypersensitivity to gluten. The incidence of DH is high in population with genetic predisposition to HLA-DQ2 or DQ8. Clinical manifestations of DH are polymorphic lesions, papulo-vesicular rash or papules-excoriations, dominated by itching. The gold standard for diagnosis is the presence of granular immunoglobulin (Ig)-A deposits in the stratum papilla dermis on DIF examination. A gluten-free diet is the mainstay of treatment. Dapsone is the drug of choice. Prognosis is good with proper diagnosis and treatment.
Downloads
References
Clarindo M, Soligo E, Ruaro R, Possebon A, Uyeda H, Empinotti J. Dermatitis herpetiformis: Pathophysiology, clinical presentation, diagnosis, and treatment. Bras Dermatol. 2014;89(6):865–77.
Antiga E, Caproni M. The diagnosis and treatment of dermatitis herpetiformis. Clin Cosmet Investig Dermatol. 2015;8:257–65.
Ohata C. Dermatitis herpetiformis: A cutaneous gluten-related disorder with possible exception in Asians patients. J Dermatol Res Ther. 2016;2(6):1–3.
Nguyen C, Kim S. Dermatitis herpetiformis: An update on diagnosis, disease monitoring, and management. Medicina (Mex). 2021;57(843):1–15.
Bonciolini V, Bonciani D, Verdelli A, D’Errico A, Antiga E, Fabbri P, et al. Newly described clinical and immunopathological feature of dermatitis herpetiformis. Clin Dev Immunol. 2012;2012:967974. doi: 10.1155/2012/967974
Handa S, Dabas G, De D, Mahajan R, Chatterjee D, Saika U, et al. A retrospective study of dermatitis herpetiformis from an immunobullous disease clinic in north India. Int J Dermatol. 2018;57(8):1–6.
Hull C, Zone J. Dermatitis herpetiformis and linear IgA bullous dermatosis. In: Bolognia JL, Schaffer JV, Cerroni L, editors. Dermatology. 4th ed. United States: Elsevier Saunders; 2018. p. 527–33.
Anwar M, Rashid A, Tahir M, Ijaz A. Guidelines for the management of dermatitis herpetiformis. J Pak Assoc Dermatol. 2013;23(4):428–35.
Vale E, Dimatos O, Porro A, Santi C. Consensus on the treatment of autoimmune bullous dermatoses: Dermatitis herpetiformis and linear IgA bullous dermatosis – Brazilian society of dermatology. Bras Dermatol. 2019;94(2):48–55.
Katz S. Dermatitis herpetiformis. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 9th ed. United States: McGraw-Hill; 2019. p. 1002–7.
Cinats A, Parsons L, Haber R. Facial involvement in dermatitis herpetiformis: A case report and review of the literature. J Cutan Med Surg. 2019;23(1):35–7.
Anokhina A, Silantyeva E, Ruvinskaya G. Clinical case of isolated lesion of oral mucosa by dermatitis herpetiformis. BioNanoscience 2020;10:311–4.
Simpson M, Cowen E, Cho S. Acral petechial eruptions without gastrointestinal symptoms: Three cases of dermatitis herpetiformis. JAAD Case Rep. 2020;6:935–8.
Weiss A, Nawrocki S, Laureano A, Scherl S, Shulman K, Kwon E. A rare case of dermatitis herpetiformis presenting as fingertip petechiae. SKIN J Cutan Med. 2020;4(1):68–71.
Kern M, Kim K, Johnson G, Hawkins S, Wong H. Dermatitis herpetiformis presenting as pseudovasculitis. JAAD Case Rep. 2017;3:444–7.
Ohata C, Ishii N, Hamada T, Shimomura Y, Niizeki H, Dainichi T, et al. Distinct characteristics in Japanese dermatitis herpetiformis: A review of all 91 Japanese patients over the last 35 years. Clin Dev Immunol. 2012;2012:562168. doi: 10.1155/2012/562168.
Antiga E, Verdelli A, Calabro A, Fabbri P, Caproni M. Clinical and immunopathological features of 159 patients with dermatitis herpetiformis: An Italian experience. G Ital Dermatol Venereol. 2013;148(2):163–9.
Lee R, Lobo Y, Spelman L. Development of dermatitis herpetiformis in chronic plaque psoriasis. Case Rep Dermatol. 2021;13:141–7.
Goh C, Pan J. Dapsone. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 9th ed. United States: McGraw-Hill; 2019. p. 3423–9.
Ralph J, Kelly A, Lally A, Kirby B. Recalcitrant dermatitis herpetiformis treated successfully with sulfasalazine. Int J Dermatol. 2020;60(4):1–2.
Wang Y, Yang B, Zhou G, Zhang F. Two cases of dermatitis herpetiformis successfully treated with tetracycline and niacinamide. Acta Dermatovenerol Croat. 2018;26(3):273–5.
Nguyen K, Gwinn C, Vary J. Rituximab treatment for dermatitis herpetiformis in the setting of type 1 diabetes mellitus, celiac disease, vitiligo, autoimmune hemolytic anemia, and autoimmune thrombocytopenia. JAAD Case Rep. 2020;6:122–3.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
